Full Press Release Details
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best in Class MTA cooperative PRMT5 Inhibitor.
IDYA
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best in Class MTA cooperative PRMT5 Inhibitor
Key Takeaway: IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best in Class MTA cooperative PRMT5 Inhibitor
Price reaction · baseline $27.79 (2024-12-06 close) · 4 other IDYA headline(s) in the window, move may be shared
day 0 close
-0.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma